The mechanism of RvD1 alleviates type 2 diabetic neuropathic pain by influencing microglia polarization in rats

doi:10.12047/j.cjap.5521.2017.067

Abstract

Abstract: Objective: To study the relationship between microglia polarization in the spinal dorsal horn and type 2 diabetic neuropathic pain (DNP). And explore the mechanism of RvD1 alleviating type 2 diabetic neuropathic pain. Methods: Type 2 diabetes mellitus (T2DM) rats came from the male SD rats which were fed by high-fat and high-sucrose diet and given intraperitoneal streptozotocin(STZ), then detected fa sting blood glucose level, the mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL), which was to prepare the type 2 DNP model rats. And they were randomly divided into 3 groups:type 2 DNP group (group D), type 2 DNP and RvD1 group (group R), type 2 DNP and solvent control group (group S), 36 rats in each group. After being given STZ 14 days, the rats of group D, R, S were placed a catheter in subarachnoid cavity. Three days later, the RvD1 10μl (10 ng/μl) and 100% ethanol 10μl were injected into subarach-noid cavity through the catheter once a day for 14 consecutive days. Another 36 normal rats were served as normal control group (group N) and were fed with common forage. MWT and TWL were measured at 1, 3, 7, 14 days after Subarachnoid injection, then the nine rats'spinal cord of the lumbar segment 4~6 were removed to detect the expression of inducible nitric oxide synthase(iNOS) and arginase 1(Arg1) by Western blot, the marker of microglia M1 and M2 polarization. Results: Compared with group N, MWT was decreased significantly and TWL was shortened, the expression of Arg1 was down-regulated and the expression of iNOS was up-regulated in spinal dorsal horn at the 1, 3, 7, 14 days in groups D and S (P < 0.05). Compared with group D, MWT was significantly increased and TWL was prolonged, the expression of Arg1 was up-regulated and the expression of iNOS was down-regulated in spinal dorsal horn at the 7, 14 days in group R (P < 0.05). There was no significant difference in the MWT, TWL and expression of Arg1 and iNOS between D and S groups. Conclusion: RvD1 promotes mi-croglia toward M2 polarization and alleviates type 2 diabetic neuropathic pain in rats.

Key words: rats, T2DM, the spinal dorsal horn, microglia polarization, RvD1, Arg1, iNOS

MA Yi-mei, LI Chuan-da, ZHU Ya-bing, XU Xia, LI Jun, CAO Hong. The mechanism of RvD1 alleviates type 2 diabetic neuropathic pain by influencing microglia polarization in rats[J]. CJAP, 2017, 33(3): 277-281.

References

[1] Lam DW, LeRoith D. The worldwide diabetes epidemic[J]. Curr Opin Endocrinol Diabetes Obes, 2012, 19(2):93-96.
[2] Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemi-ology of type 2diabetes mellitus——present and future perspec-tives[J]. Nat Rev Endocrinol, 2011, 8(4):228-236.
[3] Guan Y, Ding X, Cheng Y, et al. Efficacy of pregabalin for peripheral neuropathic pain:results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China[J]. Clin Ther, 2011, 33(2):159-66.
[4] Xu ZZ, Zhang L, Liu T, et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions[J]. Nat Med, 2010, 16(5):592-597.
[5] Quan-Xin F, Fan F, Xiang-Ying F, et al. Resolvin D1 reverses chronic pancreatitis-induced mechanical allodynia, phosphorylation of NMDA receptors, and cytokines expression in the thoracic spinal dorsal horn[J]. BMC Gastroenterol, 2012, 12(1):1-10.
[6] Ji RR, Berta T, Nedergaard M. Glia and pain:Is chronic pain a gliopathy[J]. Pain, 2013, 154(Suppl 1):S10-28.
[7] Dang JK, Wu Y, Cao H, et al. Establishment of a Rat Model of Type Ⅱ Diabetic Neuropathic Pain[J]. Pain Med, 2014, 15(4):637-646.
[8] Muniyappa R, Lee S, Chen H, et al. Current approaches for assessing insulin sensitivity and resistance in vivo:advan-tages, limitations, and appropriate usage[J]. Am J Physiol Endocrinol Metab, 2008, 294(1):15-26.
[9] Yaksh TL, Grafe MR, Malkmus S, et al. Studies on the safety of chronically admisnistered intrathecal neostigmine methylsulfate in rats and dogs[J]. Anesthesiol, 995, 82(2):412-427.
[10] Chan CC. Inflammation:beneficial or detrimental after spinal cord injury[J]. Recent Pat CNS Drug Discov, 2008, 3(3):189-199.
[11] Kigerl KA, Gensel JC, Ankeny DP, et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord[J]. J Neurosci, 2009, 29(43):13435-13444.
[12] Shechter R, Schwartz M. Harnessing monocyte derived macrophages to control central nervous system pathologies:no longer ‘if’ but ‘how’[J]. J Pathol, 2013, 229(2):332-346.
[13] Serhan CN, Hong S, Gronert K, et al. Resolvins a family of bioactive products of omega-3fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation sig-nals[J]. J Exp Med, 2002, 196(8):1025-1037.
[14] Li L, Yan W, Wang Y, et al. Resolvin D1 promotes the in-terleukin-4-induced alternative activation in BV-2microglial cells[J]. J Neuro Inf lammation, 2014, 11(1):72.
[15] Bang S, Yoo S, Yang TJ, et al. 17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3leading to peripheral antinociception[J]. Br J Pharmacol, 2012, 165(3):683-692.